Aarti Pharmalabs · NSE: AARTIPHARM · BSE: 543748

Q3 FY26 results · Oct–Dec 2025

Aarti Pharmalabs reported revenue from operations of ₹432.27 crore (down 19.6% from Q3 FY25) and net profit of ₹47.96 crore (down 35.2% from Q3 FY25) for Q3 FY26 (Oct–Dec 2025), on a consolidated basis.

Consolidated · ₹ crore
Item	Q3 FY26	Q3 FY25	YoY	Q2 FY26	QoQ
Revenue from operations	432.27	537.78	−19.6%	418.33	+3.3%
Other income	(0.37)	5.03	Turned loss	0.05	Turned loss
Total income	431.90	542.81	−20.4%	418.39	+3.2%
Profit before share of associates & JVs and tax	57.95	100.63	−42.4%	39.33	+47.3%
Share of profit/(loss) of associates & JVs	4.92	0.00		(0.64)
Net profit for the period	47.96	73.99	−35.2%	27.92	+71.7%
Attributable to shareholders of the company	46.39	73.99	−37.3%	28.57	+62.4%
EPS, basic (₹)	5.29	8.16	−35.2%	3.08	+71.8%
Net margin (%)	11.1	13.8		6.7

This company reports a share of profit/(loss) from associates and joint ventures. BSE’s filing format records that share after tax, so it is shown on its own line. The company’s own statement may add it before its “profit before tax” line.

Standalone · ₹ crore
Item	Q3 FY26	Q3 FY25	YoY	Q2 FY26	QoQ
Revenue from operations	425.25	470.95	−9.7%	417.29	+1.9%
Other income	(0.37)	11.94	Turned loss	3.15	Turned loss
Total income	424.88	482.88	−12.0%	420.44	+1.1%
Profit before tax	58.58	96.18	−39.1%	41.70	+40.5%
Net profit for the period	43.84	73.52	−40.4%	30.93	+41.8%
EPS, basic (₹)	4.84	8.11	−40.3%	3.41	+41.9%
Net margin (%)	10.3	15.6		7.4

Consolidated

Filed with BSE: 09 Feb 2026, 20:36 IST
Board meeting: 09 Feb 2026
Period: 01 Oct 2025 to 31 Dec 2025
Review status: Unaudited
Source: XBRL filing on BSE

Standalone

Filed with BSE: 09 Feb 2026, 20:36 IST
Board meeting: 09 Feb 2026
Period: 01 Oct 2025 to 31 Dec 2025
Review status: Unaudited
Source: XBRL filing on BSE